Polypeptide radionuclide complex targeting fibroblast activation protein and use thereof

By designing a polypeptide radionuclide complex targeting fibroblast activation protein, the problem of short retention time of existing FAP-targeted therapy drugs is solved, cell affinity and tumor uptake rate are improved, and better tumor treatment and performance are achieved. Like effect.

WO2024230246A1PCT designated stage expired Publication Date: 2024-11-14CHENGDU NEW RADIOMEDICINE TECH CO LTD

Patent Information

Application Number
PCT/CN2024/073244
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-01-19
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing FAP-targeted therapeutic drugs have a short retention time in the tumor site, resulting in poor treatment effect and room for improvement in cell internalization and tumor uptake.

Method used

A class of polypeptide radionuclide complexes targeting fibroblast activation proteins were designed. By optimizing the combination of polypeptide sequence and chelating groups, the enzyme inhibitory activity and cellular affinity of the drug are improved, and the tumor retention time is extended.

Benefits of technology

It significantly improves the cellular affinity and tumor uptake rate of drugs, extends tumor retention time, and is suitable for nuclide treatment and imaging of tumors with high expression of FAP protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024073244_14112024_PF_FP_ABST
    Figure CN2024073244_14112024_PF_FP_ABST
Patent Text Reader

Abstract

A compound targeting fibroblast activation protein. The compound is a combination containing urea Glu(OH)2-CO-Lys and / or Q-CO-R and a cyclic peptide of 7 amino acids, AA1-AA2-AA3-AA4-AA5-AA6-AA7. The hydrophilic fragment Glu-CO-Lys having strong polarity is introduced into the carbon terminus of the cyclic peptide to change the molecular properties, then the linking fragment is reasonably selected, and other sites are reasonably modified, so as to finally obtain a candidate molecule having higher enzyme inhibition activity, better affinity for cells and longer retention time in tumors. In addition, also provided is a polypeptide radionuclide complex targeting fibroblast activation protein. Biological test results show that the polypeptide radionuclide complex has higher enzyme inhibition activity, better affinity for cells, higher tumor uptake and longer duration, and is suitable for the nuclide therapy and imaging of tumors with high FAP protein expression.
Need to check novelty before this filing date? Find Prior Art

Description

Polypeptide radionuclide complex targeting fibroblast activation protein and its application Technical Field

[0001] The present invention relates to the fields of nuclear medicine and molecular imaging, and in particular to a polypeptide radionuclide complex targeting fibroblast activation protein and applications thereof. Background Art

[0002] Malignant tumors remain one of the major threats to human life and health, yet achieving precise diagnosis and treatment of tumors remains a significant challenge. Malignant tumors are composed of tumor cells and various non-malignant cells, which together form and shape the tumor microenvironment and tumor stroma. Because the stroma can comprise up to 90% of the total tumor volume, targeting the stroma may be more sensitive than targeting the tumor cells themselves in certain cancers. Cancer-associated fibroblasts (CAFs), a heterogeneous population of fibroblast-like cells, constitute the majority of the tumor stroma and play a crucial role in tumor growth, migration, metastasis, extracellular matrix remodeling, therapeutic resistance, and immunosuppression. Compared to cancer cells, CAFs are more genetically stable and less prone to developing therapeutic resistance, making them excellent target cells for anti-tumor therapy (Nat. Rev. Cancer 2016, 16, 582–598).

[0003] Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein belonging to the dipeptidyl peptidase 4 (DPP4) family, possessing both dipeptidyl peptidase and endopeptidase activities. Normally, FAP is only transiently expressed during embryonic development. In healthy humans, FAP is expressed only in granulation tissue during wound repair, the cervix, endometrium, pancreas, placenta, and skin, and is not ubiquitously or widely expressed in other healthy adult organs. When malignant tumors develop, fibroblasts become activated, and FAP expression is upregulated in activated fibroblasts. Studies have shown that FAP is upregulated in the stroma of over 90% of epithelial tumors. The specific expression of FAP makes it a potential target for tumor diagnosis and treatment (Proteom. Clin. Appl. 2014, 8, 454–463).

[0004] In recent years, targeted therapies for FAP have rapidly developed, with multiple FAP-targeted treatment options entering clinical trials. Radioactively targeted FAP therapies have drawn particular attention. These drugs utilize small molecules, peptides, antibodies, and other targeted agents to deliver radionuclides to tumors through their specific targeting, releasing high-energy radiation to kill tumor cells and achieve precision therapy. Haberkorn Uwe's research team at Heidelberg University in Germany has developed a series of quinoline-based small-molecule radioactive drugs for FAP diagnosis and treatment. These FAP-targeted small-molecule radioactive drugs demonstrate high specificity across a variety of primary and metastatic tumors, but exhibit high tumor clearance rates, with over 70% of the drug being metabolized and cleared from the tumor within 24 hours (WO2019154886A1; Eur. J. Nuc. Med Mol. Imag, 2022, 49, 3651–3667). This high tumor clearance rate shortens the duration of treatment, limiting its potential therapeutic potential. In 2020, 3B-Pharmaceuticals GmbH of Germany developed the FAP-targeting cyclic peptide FAP-2286 and conjugated it to a radionuclide (such as 177-Lu) for the treatment of solid tumors (WO 2022148843). Studies have shown that FAP-2286 has higher tumor uptake, longer tumor retention, and better tumor suppression than FAP-targeting small molecules. It has entered Phase I / II studies (Eur. J. Nuc. Med Mol. Imag, 2022, 49, 3651–3667). Researchers in this field know that high target cell affinity often reduces the dose of radioactive targeted therapeutics, increases drug absorption at the tumor site, and reduces radiation damage to non-target organs. Furthermore, a longer tumor retention time of peptide-conjugated radionuclide drugs often indicates better tumor treatment efficacy. Although FAP-2286 has demonstrated some potential for tumor treatment, its cellular internalization rate, tumor uptake, and tumor retention duration still need improvement. Therefore, building on existing research on FAP-targeting molecules, designing FAP-targeted peptide radiotherapeutics with novel structures, high uptake rates, and optimal metabolic properties holds significant promise for cancer patients and holds significant market potential.

[0005] Summary of the Invention

[0006] The problem underlying the present invention is to provide compounds suitable as diagnostic (imaging) agents and / or pharmaceutical agents, in particular when conjugated to diagnostically and / or therapeutically active effectors, such that the compounds are potent inhibitors of FAP activity. Another problem underlying the present invention is to provide compounds suitable as diagnostic and / or pharmaceutical agents in the diagnosis and / or treatment of diseases, in particular when conjugated to diagnostically and / or therapeutically active effectors, in which diseased cells and / or diseased tissue express FAP. A further problem underlying the present invention is to provide compounds suitable for delivering diagnostically and / or therapeutically effective agents, respectively, to diseased cells and / or diseased tissue, more particularly diseased cells and / or diseased tissue expressing FAP, preferably said diseased tissue comprising or containing cancer-associated fibroblasts. Furthermore, the problem underlying the present invention is to provide methods for diagnosing diseases, methods for treating and / or preventing diseases, and methods for the combined diagnosis and treatment of diseases; preferably, such diseases are diseases involving cells and / or tissue expressing FAP, more particularly diseased cells and / or diseased tissue expressing FAP, preferably said diseased tissue comprising or containing cancer-associated fibroblasts. Furthermore, the problem underlying the present invention is to provide a pharmaceutical composition containing a compound having the characteristics described above. Furthermore, the problem underlying the present invention is to provide a kit suitable for use in any of the methods described above.

[0007] Specifically, the purpose of the present invention is to provide the use of the targeted fibroblast activation protein (FAP) polypeptide complex in tumor radionuclide imaging and treatment.

[0008] Specific tumor applications include the diagnosis and treatment of basal cell carcinoma of the skin, oral squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, bile duct cancer, renal cell carcinoma, salivary gland cancer, sarcoma, and bladder cancer.

[0009] The object of the present invention is to provide the structure of the compound targeting fibroblast activation protein (FAP).

[0010] Another object of the present invention is to provide a complex structure of the ligand of the targeted fibroblast activation protein (FAP) compound and a radionuclide label.

[0011] The present invention provides a class of fibroblast activation protein targeting compounds, which are at least one of the compounds having the structures shown in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII and Formula IX: at least one of the compounds having the structures shown in Formula VIII and Formula IX:

[0012] According to the present invention, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX are combinations containing urea Glu(OH)2-CO-Lys and / or Q-CO-R and 7 amino acids AA1-AA2-AA3-AA4-AA5-AA6-AA7 and W to form a cyclic peptide, as well as compounds formed by them with a linking group L and a chelating group C.

[0013] According to the present invention, in the structure Q-CO-R of urea in formula II, formula VII, formula VIII, and formula IX, Q and R can be glycine, the same or different 19 natural L- or D-type amino acids, NH2-(CH2) n -COOH, NH2-(PEG) n -CH2COOH、NH2-(PEG) n -CH2CH2COOH, NH2CH3, NH2-(CH2) n -CH3、NH2-(PEG) n -CH3、NH2-(PEG) n -CH2CH3 is arbitrarily combined with amino groups to form a urea structure (n=1-18).

[0014] According to the present invention, the cyclic peptide sequence in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX comprises 7 amino acids AA1-AA2-AA3-AA4-AA5-AA6-AA7, wherein the peptide sequence is described from the nitrogen end to the carbon end; wherein any one AA in AA1-AA2-AA3-AA4-AA5-AA6-AA7 is common glycine, L or D-Hyp, L- or D-type 1-Nal or 2-Nal, and 19 L-type natural amino acids and D-type non-natural amino acid residues. Specifically, AA1-AA2-AA3-AA4-AA5-AA6-AA7 is preferably Cys-Pro-Hyp-Thr-Gln-(1-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-(2-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-Trp-Cys.

[0015] According to the present invention, W represents a cyclic structure formed by a thioether bond between tribromobenzylbenzene or dibromobenzylbenzene and the thiol groups contained in AA1 and AA7 in Formulas I, II, III, IV, V, VI, VII, VIII, or IX. Alternatively, W may represent a disulfide bond formed by direct oxidation of the thiol groups contained in AA1 and AA7.

[0016] According to the present invention, in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, L is a linking group. Specifically, L can be O, NH2CH2(CH2), nSH (n = 0-17, n = 1 is AET), Ahx, AEEA, rGlu, any one or combination of 20 L-type natural amino acids or corresponding D-type amino acids, L- or D-type 1-Nal or 2-Nal, 4-amino-piperidine-4-carboxylic acid, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, 1-piperazine-(CH2) n A linking group formed by condensing COOH (n=0-18), AET-Ahx, AET-AEEA, AET-Ahx-rGlu, AET-Ahx–rGlu-AEEA, AET-AEEA-rGlu-Ahx, AET-AEEA-AEEA–Ahx, AET-Ahx–rGlu-AEEA-AEEA, AET-AEEA-AEEA–rGlu-Ahx, and any combination thereof with a peptide chain amino group or bromide and a chelating agent C.

[0017] According to the present invention, C in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX is a group formed by a chelating agent. The chelating agent can be selected from DOTA, NOTA, NODA, NODAGA, DOTP, TETA, ATSM, PTSM, and EDTA. More preferably, it is DOTA, DOTAGA, and NOTA. Specifically, the selected chelating agent is DOTA or NOTA.

[0018] According to the present invention, X1 in Formula I, Formula II, Formula III, Formula IV, Formula V, and Formula VI is a modification group formed by an amide bond at the nitrogen end of the cyclic peptide; specifically, X1 is preferably O, acetic acid, propionic acid, phenylpropionic acid, n-hexanoic acid, n-heptanoic acid, n-octanoic acid, n-nonanoic acid, n-decanoic acid, or an isomeric acid thereof, octadecanedioic acid, Ph(CH2)nCOOH (n=0-17), or CH3O-(PEG) n -CH2COOH、CH3O-(PEG) n -CH2CH2COOH、CH3CH2O - (PEG) n -CH2COOH、CH3CH2O - (PEG) n -CH2CH2COOH (PEG = ethoxy, n = 1-16) or its isomers, or an amide residue formed with an amino group. Alternatively, X1 can be a modified group formed by an amide bond of any amino acid with an acetyl group blocking the amino group, including but not limited to Ac-Gly, Ac-Glu, Ac-Thr, Ac-Phe, or any combination thereof.

[0019] According to the present invention, Y1, Y2, X2 in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, and X1 in Formula VII, Formula VIII, and Formula IX are structural modification groups at both ends of the cyclic peptide, and the structures of Y1, Y2, X1, and X2 may be the same or different; Y1, Y2, X1, and X2 are 0, any amino acid, or a fragment formed by an amino acid and Ahx, AEEA, etc., including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-N al, Trp, Glu, rGlu, Gly, Phe, Pca, Ahx-Ahx, AEEA-AEEA, Ahx-AEEA, Gly-Ahx, rGlu-Ahx, Gly-AEEA, rGlu-AEEA, Ahx-Ahx-Gly, Ahx-Ahx-rGlu, Ahx-AEEA-rGlu, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, and any combination thereof.

[0020] According to the present invention, in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, the S linker fragment may specifically be O, glycine, 19 L-natural amino acids or corresponding D-amino acids, or compounds containing amino and carboxyl groups, including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-Nal, Gly, Glu, rGlu, and any combination thereof.

[0021] According to the present invention, the compound targeting fibroblast activation protein is more specifically the following compound:

[0022] NRT-87

[0023] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH

[0024] NRT-87D

[0025] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH

[0026] NRT-136

[0027] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-[Cys(SS)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0028] NRT-136D

[0029] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0030] NRT-137

[0031] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0032] NRT-137D

[0033] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0034] NRT-137B

[0035] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-Ahx-(Cys(DBMB)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys)-Hex)-OH

[0036] NRT-138

[0037] Glu(OH)2NH-CO-Lys((2-Nal)-Lys-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0038] NRT-138D

[0039] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0040] NRT-139

[0041] Glu(OH)2NH-CO-Lys((1-Nal)-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0042] NRT-139D

[0043] Glu(OH)2NH-CO-Lys((1-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0044] NRT-143

[0045] Glu(OH)2NH-CO-Lys(Trp-Pca-Ahx-[Cys(S-S)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH

[0046] NRT-164

[0047] Glu(OH)2NH-CO-Lys(Trp-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0048] NRT-165

[0049] Glu(OH)2NH-CO-Lys(Phe-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0050] NRT-179

[0051] Glu(OH)2NH-CO-Lys(Glu-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Lys-Hex)-OH

[0052] NRT-180

[0053] Glu(OH)2NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0054] NRT-181

[0055] Glu(OH)2NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0056] NRT-185

[0057] Glu(OH)2NH-CO-Lys(Glu-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0058] NRT-186

[0059] Glu(OH)2NH-CO-Lys(Glu-Phe-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0060] NRT-189

[0061] Glu(OH)2-CO-Lys(2-Nal-Gly-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0062] NRT-190

[0063] Glu(OH)2-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0064] NRT-191

[0065] Glu(OH)2NH-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(2-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0066] NRT-219

[0067] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0068] NRT-219D

[0069] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys ]-Hex)-OH

[0070] NRT-219L1

[0071] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0072] NRT-219L2

[0073] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0074] NRT-219L3

[0075] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-rGlu-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0076] NRT-220

[0077] Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0078] NRT-220D

[0079] Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0080] NRT-221

[0081] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH

[0082] NRT-221D

[0083] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH

[0084] NRT-222

[0085] Glu(OH)2NH-CO-Lys(Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0086] NRT-223

[0087] Glu(OH)2NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0088] NRT-223D

[0089] Glu(OH)2NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0090] NRT-224

[0091] Glu(OH)2NH-CO-Lys(Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0092] NRT-225

[0093] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH

[0094] NRT-226

[0095] Glu(OH)2NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0096] NRT-226D

[0097] Glu(OH)2NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0098] NRT-227

[0099] Glu(OH)2NH-CO-Lys(Ahx-Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0100] NRT-228

[0101] Glu(OH)2NH-CO-Lys(Ahx-AEEA-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0102] NRT-230

[0103] Glu(OH)2NH-CO-Lys(Ac)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH

[0104] NRT-231

[0105] Glu(OH)2NH-CO-Lys(Hex)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH

[0106] NRT-232

[0107] Glu(OH)2NH-CO-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH

[0108] NRT-233

[0109] Glu(OH)2NH-CO-Ahx-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH

[0110] NRT-234

[0111] Glu(OH)2NH-CO-Lys(Hex)-Gly-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH

[0112] NRT-235

[0113] Glu(OH)2NH-CO-Lys(Hex)-AEEA-[Cys(TBMB-AET)-Pro-Hyp-Thr-Glu-(1-Nal)-Cys]-Glu

[0114] NRT-236

[0115] Glu(OH)2NH-CO-Lys(PPA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu

[0116] NRT-237

[0117] Glu(OH)2NH-CO-Lys(PA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu

[0118] NRT-238

[0119] Glu(OH)2NH-CO-Lys(CH3PEG2)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu

[0120] NRT-239

[0121] Glu(OH)2NH-CO-Lys(Glu-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0122] NRT-240

[0123] Glu(OH)2NH-CO-Lys(Glu-Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0124] NRT-241

[0125] Glu(OH)2NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0126] NRT-242

[0127] Glu(OH)2NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0128] NRT-243

[0129] Glu(OH)2NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH

[0130] NRT-244

[0131] Glu(OH)2NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH

[0132] According to the present invention, the compound targeting fibroblast activation protein can also be radionuclide labeled to obtain a polypeptide radionuclide complex targeting fibroblast activation protein; specifically, the polypeptide radionuclide complex targeting fibroblast activation protein is a complex obtained by labeling a radionuclide with a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, or Formula IX of the present invention as a ligand; the radionuclide includes: 89 Zr, 44 Sc, 111 ln、 90 Y. 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 64 Cu, 67 Cu, 149 Tb, 152 Tb, 161 Tb, 203 Pb, 212 Pb, 153 Gd, 155 Gd, 123 I. 125 I. 131 I. 18 F. 157 Gd, 213 Bi, 225 Ac, 230 U. 223 Ra, 165 Second, 18 F and 177 More specifically, the radionuclide used for diagnosis is preferably 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 ln and 18 F. The radionuclide used for treatment is preferably 90 Y. 177 Lu, 255 Ac.

[0133] According to the present invention, the compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX or their pharmaceutically acceptable salts can be used to prepare radionuclide therapy or imaging drugs for tumors with high FAP protein expression.

[0134] According to the present invention, the polypeptide radionuclide complex targeting fibroblast activation protein can be applied to the radionuclide therapy or imaging of tumors with high expression of FAP protein.

[0135] The present invention also provides a composition comprising a compound according to Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, or Formula IX, a polypeptide radionuclide complex targeting fibroblast activation protein, and a pharmaceutically acceptable excipient. The composition can be used for radionuclide therapy or imaging of tumors with high FAP protein expression.

[0136] According to the present invention, the above-mentioned compound, complex or composition is prepared into an injection and administered by intravenous injection for patients with tumors with high FAP protein expression; the tumors with high FAP protein expression include but are not limited to basal cell carcinoma of the skin, oral squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, bile duct cancer, renal cell carcinoma, salivary gland cancer, sarcoma, and bladder cancer.

[0137] According to the present invention, a kit is also provided, which comprises the above-mentioned compound, complex composition, one or more optional excipients and optionally one or more devices, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analysis device or an administration device.

[0138] One skilled in the art will recognize that a or the compound of the present invention is any compound disclosed herein, including but not limited to any compound described in any of the above embodiments and any of the following embodiments.

[0139] One skilled in the art will recognize that one or the methods of the present invention is any method disclosed herein, including but not limited to any method described in any of the above embodiments and any of the following embodiments.

[0140] One skilled in the art will recognize that a or the composition of the present invention is any composition disclosed herein, including but not limited to any composition described in any of the above embodiments and any of the following embodiments.

[0141] One skilled in the art will recognize that a or the kit of the present invention is any kit disclosed herein, including but not limited to any kit described in any of the above embodiments and any of the following embodiments.

[0142] The present invention introduces a highly polar hydrophilic fragment Glu-CO-Lys at the carbon end of the cyclic peptide to change the molecular properties, and then rationally selects the connecting fragment and combines it with rational modification of other sites to ultimately obtain a candidate molecule with higher enzyme inhibitory activity, better cell affinity and longer tumor retention time.

[0143] The present invention provides a polypeptide radionuclide complex targeting fibroblast activation protein and its application. Biological test results show that the complex has higher enzyme inhibition activity, better cell affinity, higher tumor uptake, and longer maintenance time. It is suitable for use as a radionuclide therapy and imaging of tumors with high FAP protein expression. BRIEF DESCRIPTION OF THE DRAWINGS

[0144] Figure 1 68 Ga-FAP-2286, 68 Ga-NRT-136D, 68 Ga-NRT-137D, 68 Figure 3: Cell affinity experiment of Ga-NRT-138D in the FAP-positive cell line U87;

[0145] Figure 2 68 Ga-FAP-2286, 68 Ga-NRT-136D, 68 Ga-NRT-137D, 68 Figure 3: Cell affinity experiment of Ga-NRT-138D in the FAP-positive cell line HEK-293-FAP;

[0146] Figure 3 68 Ga-FAP-2286, 68 Ga-NRT-219D, 68 Ga-NRT-220D, 68 Figure 3: Cell affinity experiment of Ga-NRT-221D in the FAP-positive cell line U87;

[0147] Figure 4 shows 68 Ga-FAP-2286, 68 Ga-NRT-219D, 68 Ga-NRT-220D, 68 Figure 3: Cell affinity experiment of Ga-NRT-221D in the FAP-positive cell line HEK-293-FAP;

[0148] Figure 5 177 SPECT imaging results of Lu-FAP-2286 in tumor model mice;

[0149] Figure 6 177 SPECT imaging results of Lu-NRT-219D in tumor model mice. DETAILED DESCRIPTION

[0150] Polypeptide synthesis: The fibroblast activation protein ligand polypeptide involved in the present invention is synthesized based on the Fmoc solid phase peptide synthesis method.

[0151] The solid-phase synthesis of the Glu-CO-Lys urea structure is as follows: 3 mmol of a solution of bis(tert-butyl)-L-glutamic acid hydrochloride in dry dichloromethane (200 mL) and 3 mL of N-ethyldiisopropylamine (DIPEA) are slowly added dropwise to a solution of 1 mmol of triphosgene in dry dichloromethane (10 mL) at 5°C. After the addition is complete, the reaction is continued for 3 hours. The reaction solution is then added to 0.5 mmol of Lys(Alloc)-CTC resin and the reaction is continued with gentle stirring for 16 hours. 50 mg of tetrakis(triphenylphosphine)palladium and 400 μL of morpholine are then added, and the reaction is continued for 3 hours to remove the Alloc protecting group.

[0152] The connection of other amino acid fragments was continued in sequence by solid phase synthesis of linear peptides according to the Fmoc solid phase peptide synthesis method.

[0153] After solid-phase synthesis of the linear peptide is completed, a cleavage solution containing ethanedithiol is added for cleavage. After cleavage, precipitation is performed using methyl tert-butyl ether. The solid is separated by centrifugation, the supernatant is discarded, and the crude linear peptide is obtained by vacuum drying.

[0154] Preparation of cyclic peptides:

[0155] Cyclization Method 1: Dissolve the crude peptide (approximately 100 mg) in 100 mL of a 1:1 mixture of 50 mM ammonium bicarbonate (pH 8.5) and acetonitrile. Add 1.5 equivalents of 1,3,5-tris(bromomethyl)benzene to the mixture. Stir the solution for 1 hour, then add 10 equivalents of β-mercaptoethylamine and continue the reaction for 2 hours. After completion of the reaction, purify by preparative HPLC and lyophilize to obtain the product.

[0156] Cyclization Method 2: Dissolve the crude peptide (approximately 100 mg) in 100 mL of a 1:1 mixture of ammonium bicarbonate (50 mM, pH 8.5) and acetonitrile. Add 1.1 equivalents of 1,3-bis(bromomethyl)benzene to the mixture, and stir for 1 hour. After completion of the reaction, purify by preparative HPLC and lyophilize to obtain the product.

[0157] Cyclization Method 3: Disulfide Cyclization: Dissolve 50 μmol of the crude cleaved linear peptide in 60 mL of a 1:1 mixture of acetonitrile and 0.1 M ammonium acetate buffer. Add 50 μmol of [Pt(en)2Cl2]Cl2 ([dichloro-bis(ethylenediamine)-platinum(IV)] chloride) and continue stirring. After completion of the cyclization reaction, monitor the reaction by LC-MS. Purify the product by preparative HPLC and lyophilize to obtain the product.

[0158] Connection of chelating group C:

[0159] Dissolve 20 μmol of the cyclic peptide intermediate in 300 μl of DMSO, add 5 μl of diisopropylethylamine, and then add 200 μl of a DMSO solution of DOTA-NHS (30 μmol). Stir the reaction at room temperature and monitor by LCMS until the reaction is complete.

[0160] The known fibroblast activation protein inhibitor FAP-2286 (developed by 3B-Pharmaceuticals GmbH, Germany) involved in this invention was synthesized using the Fmoc-based solid-phase peptide synthesis method to complete the linear peptide synthesis. FAP-2286 was synthesized using the cyclization method 1 and the chelating group C connection method described in this invention.

[0161] Table 1 Abbreviations, names and structures of chemical groups in the present invention

[0162] Table 2 Sequences, calculated molecular masses, and accurate measured molecular masses of compounds determined by LCMS

[0163] Example: Nuclide Labeling

[0164] 68 Ga labeling

[0165] Take 500 μL of buffer (1.2M sodium acetate aqueous solution) to the vial, add 4 μL of NRT-87D aqueous solution (1mM / L), and then add 200 μL of about 1mCi of 68 GaCl3 solution (eluted from a gallium germanium generator) was placed on a preheated heater at 95°C for 15 minutes, then cooled for 5 minutes after stopping heating, and the radiochemical purity was determined by Radio-HPLC.

[0166] This example also uses the same labeling method to label FAP-2286D, NRT-136D, NRT-137D, NRT-138D, NRT-219D, NRT-220D, and NRT-221D. 68 The Ga mark is not described in detail here.

[0167] 68 Ga-NRT-87D

[0168] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-Phe-Gln-Thr-Pro-Pro-Cy s]-Hex)-OH

[0169] 68 Ga-NRT-136D

[0170] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0171] 68 Ga-NRT-137D

[0172] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0173] 68 Ga-NRT-138D

[0174] Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0175] 68 Ga-NRT-219D

[0176] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0177] 68 Ga-NRT-220D

[0178] Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH

[0179] 68 Ga-NRT-221D

[0180] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH

[0181] 68 Ga-FAP-2286

[0182] Hex-[Cys(TBMB-AET-DOTA- 68 Ga)‐Pro‐Pro‐Thr‐Gln‐Phe‐Cys]‐OH

[0183] 177 Lu's mark:

[0184] Mix 25 μL of NRT-87D aqueous solution (1 mM / L) with 175 μL of 0.5 M sodium acetate buffer and 0.5 M sodium ascorbate buffer (pH = 4.5). 177 Lu (about 3.5 mCi) solution was mixed therewith and heated to 95°C for 20 minutes, cooled for 5 minutes, and the radiochemical purity was determined by Radio-HPLC.

[0185] This example also uses the same labeling method to label NRT-219D and FAP-2286. 177 Lu mark, no further description is given here.

[0186] 177 Lu-NRT-87D

[0187] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH

[0188] 177 Lu-NRT-219D

[0189] Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-(1-Nal)-Gln-Thr-Hyp-Pr o-Cys]-Hex)-OH

[0190] 177 Lu-FAP-2286

[0191] Hex-[Cys(TBMB-AET-DOTA- 177 Lu)‐Pro‐Pro‐Thr‐Gln‐Phe‐Cys]‐OH

[0192] Radiochemical purity analysis method:

[0193] The radiochemical purity of the radionuclide-labeled compounds was determined using a high-performance liquid chromatograph connected to a radioactivity detector (Radio-HPLC). Instrument: Ultra-High-Performance Liquid Chromatograph (ACQUIY ARC UHPLC, Waters), Radioactive Thin-Layer Scanner (MS-2000FP, Ecker & Ziegler). Mobile phase: 0.1% trifluoroacetic acid in water and acetonitrile.

[0194] FAP half-maximal inhibitory concentration IC50 test:

[0195] Recombinant human FAP (Acro, FAP-H5244) was diluted to a concentration of 0.4 nM in assay buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1 mg / ml (0.01%) BSA, pH 7.4). 40 μl of the FAP solution was mixed with 100 nl of a three-fold serial dilution of the test compound and centrifuged at 1000 rpm for 1 minute. Z-Gly-Pro-AMC (CAS: 68542-93-98) substrate was then added to a final concentration of 10 μM, centrifuged at 1000 rpm for 1 minute, and sealed in a black 384-well opaque black plate (Perkin Elmer) for incubation at room temperature for 60 minutes. After centrifugation at 1000 rpm for 1 minute, the plate was read on an Envision. FAP can hydrolyze the fluorescent substrate Z-Gly-Pro-AMC to produce highly fluorescent AMC. The emission wavelength of AMC is between 390 and 460 nM. The fluorescence signal value can be easily detected by the program set on the Envision. Four-parameter logistic (4PL) curve fitting and IC50 calculation are performed using Prism software. IC50 value calculation: The inhibition rate values ​​of each compound concentration are imported into Graphpad Prism, and concentration-effect curve fitting and IC50 value calculation are performed. The Prism S-shaped curve fitting formula is: log (inhibitor) vs. response - variable slope: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC50-X)*HillSlope)).

[0196] Table 3 FAP half-maximal inhibitory concentration of polypeptide sequences

[0197] Cell affinity test:

[0198] The cultured U87 and HEK-293-FAP cells were digested with 0.25% trypsin (Hyclone SH30042.01), and the cells were collected and washed with 4°C 1× PBS buffer (Hyclone SH30256.01). After counting, the cells were diluted with complete DMEM medium (DMEM medium, Hyclone SH30243.01; 10% FBS, Gibco 10100147; 1% double antibody, Hyclone SV30010) to a volume of 1×10 5The cells were inoculated into 6-well plates with 1 mL per well and the experiment was carried out after 24 hours of adhesion. After 24 hours, the culture medium in the wells was replaced with 2 mL of serum-free DMEM medium (Hyclone SH30243.01) and incubated for 2 hours. After 2 hours, the culture medium was aspirated and 1 mL of serum-free DMEM medium (Hyclone SH30243.01) was added. 68 Ga-labeled test substance 68 Ga-NRT-136D, shake well after adding the sample, and incubate at 37 ° C, 5% CO2 for 1 hour. After the incubation, wash each well of cells with PBS solution (Hyclone SH30256.01) until the washing solution is free of radioactivity. Lyse the cells with 0.5 mL of 1M sodium hydroxide (Macklin S817974-1L), then wash twice with 0.5 mL of PBS solution (Hyclone SH30256.01), collect the sodium hydroxide solution and PBS solution, and count them in a gamma counter. Cell uptake is calculated as the percentage of radioactivity bound to the cells and the initial addition: AD%.

[0199] This example also uses the same cell affinity test method to test 68 Ga-labeled test substance 68 Ga-FAP-2286, 68 Ga-NRT-137D, 68 Ga-NRT-138D, 68 Ga-NRT-219D, 68 Ga-NRT-220D, 68 Ga-NRT-221D underwent cell affinity testing, which will not be described in detail here.

[0200] As can be seen from Figures 1 and 2, 68 Ga-NRT-136D, 68 Ga-NRT-137D, 68 The uptake of the three Ga-NRT-138D compounds in the two FAP-positive cell lines U87 and HEK-293-FAP was significantly better than that of the positive compound FAP-2286. 68 The uptake of Ga-NRT-136D in HEK-293-FAP was approximately 6.3 times that of FAP-2286, which was significantly better than FAP-2286.

[0201] As can be seen from Figures 3 and 4, 68 The uptake of Ga-NRT-219D in two FAP-positive cell lines, U87 and HEK-293-FAP, was significantly better than that of positive compounds. 68Ga-FAP-2286, 68 The uptake of Ga-NRT-219D in U87 cell line was approximately 68 5.0 times that of Ga-FAP-2286.

[0202] SPECT-CT imaging:

[0203] The cultured HEK-293-FAP cells were digested with 0.25% trypsin, and the cells were collected and washed with 4°C PBS buffer. After counting, the cells were prepared into 2×10 7 After 3 days of adaptive feeding, female NOG mice (18-22 g, 6-8 weeks old) were anesthetized with isoflurane, the right hind limbs were shaved, and 100 μl of cell suspension was subcutaneously inoculated. 3 After the mice were fixed, the test substance (200 μCi) was injected into the mice via the tail vein, and SPECT / CT imaging was performed at 24h, 48h, and 72h after injection.

[0204] As can be seen from Figures 5 and 6, 177 Lu-NRT-219D accumulates significantly in the tumor site of mice, and the tumor imaging is clearly visible within 24-72 hours. 177 Lu-FAP-2286, 177 Imaging results of Lu-NRT-219D at 48 and 72 hours showed that its tumor uptake was higher and lasted longer.

[0205] Although the present invention has been described in detail above using general explanations, specific embodiments, and experiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the present invention. Therefore, such modifications and improvements, which do not depart from the spirit of the present invention, are intended to be within the scope of protection claimed herein.

Claims

1. The targeted fibroblast activation protein compound has at least one of the structural compounds shown in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII and Formula IX: in, In the structure Q-CO-R of the urea in formula II, formula VII, formula VIII, and formula IX, Q and R are glycine, the same or different 19 natural L- or D-type amino acids, NH2-(CH2) n -COOH, NH2-(PEG) n -CH2COOH、NH2-(PEG) n -CH2CH2COOH, NH2CH3, NH2-(CH2) n -CH3, NH2-(PEG) n -CH3、NH2-(PEG) n -Urea structure (n=1-18) formed by any combination of CH2CH3 and amino groups; Any one of AA1-AA2-AA3-AA4-AA5-AA6-AA7 is common glycine, L- or D-Hyp, L- or D-form 1-Nal or 2-Nal, 19 L-form natural amino acids, and D-form non-natural amino acid residues; W is a cyclic structure formed by forming a thioether bond between tribromobenzylbenzene or dibromobenzylbenzene and the thiol groups contained in AA1 and AA7; or, W is a disulfide bond generated by direct oxidation of the sulfhydryl groups contained in AA1 and AA7; L is a linking group; C is a group formed by a chelating agent; In Formula I, Formula II, Formula III, Formula IV, Formula V and Formula VI, X1 is a modification group formed by an amide bond at the nitrogen end of the cyclic peptide or a modification group formed by an amide bond of any amino acid whose amino group is blocked by an acetyl group, or any combination thereof; In Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, Y1, Y2, and X2, and in Formula VII, Formula VIII, and Formula IX, X1 are structural modification groups at both ends of the cyclic peptide; S is a connecting fragment.

2. The compound according to claim 1, characterized in that: The AA1-AA2-AA3-AA4-AA5-AA6-AA7 is Cys-Pro-Hyp-Thr-Gln-(1-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-(2-Nal)-Cys or Cys-Pro-Hyp-Thr-Gln-Trp-Cys.

3. The compound according to claim 1, characterized in that: The L is a connecting group, specifically O, NH2CH2(CH2) n SH (n = 0-17, n = 1 is AET), Ahx, AEEA, rGlu, Gly, any one or a combination of 19 L-type natural amino acids or corresponding D-type amino acids, L- or D-type 1-Nal or 2-Nal, 4-amino-piperidine-4-carboxylic acid, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, 1-piperazine-(CH2) n A linking group formed by condensing COOH (n=0-18), AET-Ahx, AET-AEEA, AET-Ahx-rGlu, AET-Ahx–rGlu-AEEA, AET-AEEA-rGlu-Ahx, AET-AEEA-AEEA–Ahx, AET-Ahx–rGlu-AEEA-AEEA, AET-AEEA-AEEA–rGlu-Ahx, and any combination thereof with a peptide chain amino group or bromide and a chelating agent C.

4. The compound according to claim 1, characterized in that: The chelating agent is selected from DOTA, NOTA, NODA, NODAGA, DOTP, TETA, ATSM, PTSM, and EDTA.

5. The compound according to claim 1, characterized in that: In formula I, formula II, formula III, formula IV, formula V, and formula VI, X1 is a modification group formed by an amide bond at the nitrogen end of the cyclic peptide; specifically, X1 is O, acetic acid, propionic acid, phenylpropionic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, or isomeric acids thereof, octadecanedioic acid, Ph(CH2)nCOOH (n=0-17), or CH3O-(PEG) n -CH2COOH, CH3O-(PEG) n -CH2CH2COOH, CH3CH2O - (PEG) n -CH2COOH, CH3CH2O - (PEG)- n -CH2CH2COOH (PEG = ethoxy, n = 1-16) or its isomers, an amide residue formed with an amino group; or, X1 is a modification group formed by an amide bond of any amino acid in which the amino group is blocked by an acetyl group, including but not limited to Ac-Gly, Ac-Glu, Ac-Thr, Ac-Phe, or any combination thereof.

6. The compound according to claim 1, characterized in that: In Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, Y1, Y2, X2, and X1 in Formula VII, Formula VIII, and Formula IX are structural modification groups at both ends of the cyclic peptide, and the structures of Y1, Y2, X1, and X2 may be the same or different; Y1, Y2, X1, and X2 are 0, any amino acid, or a fragment formed by an amino acid and Ahx, AEEA, etc., including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-Nal, Trp, Glu, rGlu, Gly, Phe, Pca, Ahx-Ahx, AEEA-AEEA, Ahx-AEEA, Gly-Ahx, rGlu-Ahx, Gly-AEEA, rGlu-AEEA, Ahx-Ahx-Gly, Ahx-Ahx-rGlu, Ahx-AEEA-rGlu, 4-aminomethylbenzoic acid, 4-(aminomethyl)cyclohexanecarboxylic acid, and any combination thereof.

7. The compound according to claim 1, characterized in that: In Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, S is a linker fragment. Specifically, S is O, glycine, 19 kinds of L-type natural amino acids or corresponding D-type amino acids or compounds containing amino and carboxyl groups, including but not limited to Ahx, AEEA, Lys, 1-Nal, 2-Nal, Gly, Glu, rGlu, and any combination thereof.

8. The compound according to any one of claims 1 to 7, characterized in that: The compound is selected from: NRT-87 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH NRT-87D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH NRT-136 Glu(OH)2NH-CO-Lys((2-Nal)-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-136D Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-137 Glu(OH)2NH-CO-Lys((2-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-137D Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-137B Glu(OH)2NH-CO-Lys((2-Nal)-Lys-Ahx-(Cys(DBMB)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys)-Hex)-OH NRT-138 Glu(OH)2NH-CO-Lys((2-Nal)-Lys-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-138D Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-139 Glu(OH)2NH-CO-Lys((1-Nal)-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-139D Glu(OH)2NH-CO-Lys((1-Nal)-Lys(DOTA)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-143 Glu(OH)2NH-CO-Lys(Trp-Pca-Ahx-[Cys(S-S)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH NRT-164 Glu(OH)2NH-CO-Lys(Trp-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-165 Glu(OH)2NH-CO-Lys(Phe-Lys-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-179 Glu(OH)2NH-CO-Lys(Glu-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Lys-Hex)-OH NRT-180 Glu(OH)2NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-Trp-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-181 Glu(OH)2NH-CO-Lys(Glu-Lys-Gly-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-185 Glu(OH)2NH-CO-Lys(Glu-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-186 Glu(OH)2NH-CO-Lys(Glu-Phe-Lys-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-189 Glu(OH)2-CO-Lys(2-Nal-Gly-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-190 Glu(OH)2-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-191 Glu(OH)2NH-CO-Lys((1-Nal)-Lys-Ahx-[Cys(S-S)-(2-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219L1 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219L2 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-219L3 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-AEEA-AEEA-rGlu-Ahx-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-220 Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-220D Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-221 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH NRT-221D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH NRT-222 Glu(OH)2NH-CO-Lys(Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-223 Glu(OH)2NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-223D Glu(OH)2NH-CO-Lys(Ahx-Ahx-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-224 Glu(OH)2NH-CO-Lys(Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-225 Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH NRT-226 Glu(OH)2NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-226D Glu(OH)2NH-CO-Lys(Ahx-Glu-[Cys(TBMB-AET-DOTA)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-227 Glu(OH)2NH-CO-Lys(Ahx-Ahx-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-228 Glu(OH)2NH-CO-Lys(Ahx-AEEA-Glu-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-230 Glu(OH)2NH-CO-Lys(Ac)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-231 Glu(OH)2NH-CO-Lys(Hex)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-232 Glu(OH)2NH-CO-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-233 Glu(OH)2NH-CO-Ahx-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-234 Glu(OH)2NH-CO-Lys(Hex)-Gly-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu-OH NRT-235 Glu((OH)2NH-CO-Lys(Hex)-AEEA-[Cys(TBMB-AET)-Pro-Hyp-Thr-Glu-(1-Nal)-Cys]-Glu NRT-236 Glu(OH)2NH-CO-Lys(PPA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu NRT-237 Glu(OH)2NH-CO-Lys(PA)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu NRT-238 Glu(OH)2NH-CO-Lys(CH3PEG2)-Ahx-[Cys(TBMB-AET)-Pro-Hyp-Thr-Gln-(1-Nal)-Cys]-Glu NRT-239 Glu(OH)2NH-CO-Lys(Glu-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-240 Glu(OH)2NH-CO-Lys(Glu-Ahx-Gly-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-241 Glu(OH)2NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-242 Glu(OH)2NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH NRT-243 Glu(OH)2NH-CO-Lys(Gly-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH NRT-244 Glu(OH)2NH-CO-Lys(Glu-Ahx-[Cys(TBMB-AET)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Glu-OH 9. A polypeptide radionuclide complex targeting fibroblast activation protein, which is a complex obtained by labeling a radionuclide with a compound according to any one of claims 1 to 8 as a ligand; the radionuclide comprises: 89 Zr, 44 Sc, 111 ln, 90 Y. 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 64 Cu, 67 Cu, 149 Tb, 152 Tb, 161 Tb, 203 Pb, 212 Pb, 153 Gd, 155 Gd, 123 I. 125 I. 131 I. 18 F. 157 Gd, 213 Bi, 225 Ac, 230 U. 223 Ra, 165 2. 18 F and 177 Lu; the radionuclides used for diagnosis are 64 Cu, 68 Ga, 89 Zr, 99m Tc, 111 ln, 18 F, the radionuclide used for treatment is 90 Y. 177 Lu, 255 Ac.

10. A polypeptide radionuclide complex targeting fibroblast activation protein, the structural formula of which is shown below: 68 Ga-NRT-87D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-Phe-Gln-Thr-Pro-Pro-Cy s]-Hex)-OH 68 Ga-NRT-136D Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-137D Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-Ahx-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-138D Glu(OH)2NH-CO-Lys((2-Nal)-Lys(DOTA- 68 Ga)-AEEA-[Cys(S-S)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH <h2 style=";text-align:left;direction:ltr"> 68 <h2 style=";text-align:left;direction:ltr"> Ga-NRT-219D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-220D Glu(OH)2NH-CO-Lys(AEEA-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 68 Ga-NRT-221D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 68 Ga)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-Gly-OH 177 Lu-NRT-87D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-Phe-Gln-Thr-Pro-Pro-Cys]-Hex)-OH <h2 style=";text-align:left;direction:ltr"> 177 <h2 style=";text-align:left;direction:ltr"> Lu-NRT-219D Glu(OH)2NH-CO-Lys(Ahx-[Cys(TBMB-AET-DOTA- 177 Lu)-(1-Nal)-Gln-Thr-Hyp-Pro-Cys]-Hex)-OH 11. Use of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof in the preparation of a radionuclide therapy or imaging drug for tumors with high expression of FAP protein.

12. Use of the complex according to claim 9 or 10 in radionuclide therapy or imaging of tumors with high expression of FAP protein.

13. A composition, wherein the composition comprises the compound, complex and pharmaceutically acceptable excipient according to any one of claims 1 to 8, 9 and 10.

14. Use of the composition according to claim 13 in radionuclide therapy or imaging of tumors with high expression of FAP protein.

15. The use according to any one of claims 11, 12 or 14, characterized in that: The compound, complex or composition is prepared into an injection and administered by intravenous injection for patients with tumors with high expression of FAP protein; the tumors with high expression of FAP protein include but are not limited to basal cell carcinoma of the skin, oral squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, bile duct cancer, renal cell carcinoma, salivary gland cancer, sarcoma, and bladder cancer.

16. A kit comprising a compound according to any one of claims 1-8, 9, 10, 13, a complex composition, one or more optional excipients, and optionally one or more devices, wherein the device is selected from a labeling device, a purification device, a manipulation device, a radiation protection device, an analysis device, or an administration device.

Citation Information

Patent Citations

  • Therapeutic drug targeting fibroblast activating protein and preparation method thereof

    CN113621021A

  • Compounds comprising fibroblast activating protein ligands and uses thereof

    CN114341158A

  • Compound targeting FAP (fibroblast activating protein) as well as preparation method and application of compound

    CN115260160A

  • Compounds comprising a fibroblast activation protein ligand and use thereof

    WO2022148843A1

Cited By

  • Fibroblast activated protein targeted diagnosis and treatment integrated molecular probe

    CN120025399A

  • FGFR2-targeted polypeptide nuclide ligand, probe and application of FGFR2-targeted polypeptide nuclide ligand

    CN120025408A

  • Fibroblast activation protein ligand and use thereof

    WO2026149529A1